-
EP3878515
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3878515
| EP3878515 - THERAPEUTIC AGENT TARGETING HER2 [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 22.07.2022 Database last updated on 19.10.2024 | |
| Former | The application has been published Status updated on 13.08.2021 | Most recent event Tooltip | 22.07.2022 | Application deemed to be withdrawn | published on 24.08.2022 [2022/34] | Applicant(s) | For all designated states Hober Biotech AB Hårdvallsgatan 14 115 46 Stockholm / SE | [2021/37] | Inventor(s) | 01 /
HOBER, Sophia Hårdvallsgatan 14 115 46 Stockholm / SE | 02 /
WITTING, Emma von Paternostervägen 70 12 149 Johanneshov / SE | 03 /
GAROUSI, Javad Strindbergsgatan 25 75 421 Uppsala / SE | 04 /
TOLMACHEV, Vladimir Stenhagsvägen 255 75 266 Uppsala / SE | [2021/50] |
| Former [2021/37] | 01 /
HOBER, Sofia Hårdvallsgatan 14 115 46 Stockholm / SE | ||
| 02 /
WITTING, Emma von Paternostervägen 70 12 149 Johanneshov / SE | |||
| 03 /
GAROUSI, Javad Strindbergsgatan 25 75 421 Uppsala / SE | |||
| 04 /
TOLMACHEV, Vladimir Stenhagsvägen 255 75 266 Uppsala / SE | Representative(s) | Kransell & Wennborg KB P.O. Box 27834 115 93 Stockholm / SE | [2021/37] | Application number, filing date | 20161922.8 | 09.03.2020 | [2021/37] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3878515 | Date: | 15.09.2021 | Language: | EN | [2021/37] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 29.05.2020 | Classification | IPC: | A61P35/00, C07K14/31, C07K14/315 | [2021/37] | CPC: |
C07K14/31 (EP);
A61K51/081 (US);
A61P35/00 (EP,US);
C07K14/315 (EP);
C07K2319/31 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/37] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | HER2 ZIELENDER THERAPEUTISCHER WIRKSTOFF | [2021/37] | English: | THERAPEUTIC AGENT TARGETING HER2 | [2021/37] | French: | AGENT THÉRAPEUTIQUE CIBLANT HER2 | [2021/37] | Examination procedure | 16.03.2022 | Application deemed to be withdrawn, date of legal effect [2022/34] | 05.04.2022 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2022/34] | Fees paid | Penalty fee | Additional fee for renewal fee | 31.03.2022 | 03 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [YD]WO2014076179 (AFFIBODY AB [SE]) [YD] 1-15 * abstract * * sequences 1-12 *; | [Y] - GUO RUI ET AL, "Fusion of an albumin-binding domain extends the half-life of immunotoxins", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, (20160722), vol. 511, no. 1, doi:10.1016/J.IJPHARM.2016.07.046, ISSN 0378-5173, pages 538 - 549, XP029698825 [Y] 1-15 * abstract * * 2.2. Protein construction, expression and purification.; page 540 * DOI: http://dx.doi.org/10.1016/j.ijpharm.2016.07.046 | [Y] - JOHN LFBLOM ET AL, "Non-immunoglobulin based protein scaffolds", CURRENT OPINION IN BIOTECHNOLOGY, vol. 22, no. 6, doi:10.1016/J.COPBIO.2011.06.002, ISSN 0958-1669, (20110702), pages 843 - 848, (20110609), XP028397472 [Y] 1-15 * Affibody molecules; page 844 * DOI: http://dx.doi.org/10.1016/j.copbio.2011.06.002 | [Y] - HAO LIU ET AL, "Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain", INTERNATIONAL JOURNAL OF ONCOLOGY, (20150604), vol. 47, no. 2, doi:10.3892/ijo.2015.3027, pages 601 - 609, XP055525850 [Y] 1-15 * abstract * * page 602, column l, line 15 - line 53 * * figure 1 * * Gene construction; page 602, column r * DOI: http://dx.doi.org/10.3892/ijo.2015.3027 | [Y] - HAO LIU ET AL, "Potent and specific fusion toxins consisting of a HER2-binding, ABD-derived affinity protein, fused to truncated versions of Pseudomonas exotoxin?A", INTERNATIONAL JOURNAL OF ONCOLOGY, GR, (20190528), doi:10.3892/ijo.2019.4814, ISSN 1019-6439, XP055697025 [Y] 1-15 * abstract * * page 310, column l, line 20 - column r, line 22 * * page 311, column l, line 5 - line 7 * DOI: http://dx.doi.org/10.3892/ijo.2019.4814 | [Y] - A. ORLOVA ET AL, "Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule-Albumin-Binding Domain Fusion Protein", THE JOURNAL OF NUCLEAR MEDICINE, US, (20130325), vol. 54, no. 6, doi:10.2967/jnumed.112.110700, ISSN 0161-5505, pages 961 - 968, XP055697035 [Y] 1-15 * abstract * * page 962, column r, line 11 - line 37 * DOI: http://dx.doi.org/10.2967/jnumed.112.110700 | [Y] - TOLMACHEV VLADIMIR ET AL, "Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20070315), vol. 67, no. 6, doi:10.1158/0008-5472.CAN-06-1630, ISSN 0008-5472, pages 2773 - 2782, XP002488609 [Y] 1-15 * abstract * DOI: http://dx.doi.org/10.1158/0008-5472.CAN-06-1630 | by applicant | WO2012004384 | WO2014076179 | EP2590993 | EP2933262 | - ALTAI MWESTERLUND KVELLETTA JMITRAN BHONARVAR HKARLSTROM AE, "Evaluation of affibody molecule-based PNA-mediated radionuclide pretargeting: Development of an optimized conjugation protocol and Lu labeling", Nucl MedBiol., (20171100), vol. 54, doi:10.1016/j.nucmedbio.2017.07.003, pages 1 - 9, XP085258094 DOI: http://dx.doi.org/10.1016/j.nucmedbio.2017.07.003 | - GAROUSI JLINDBO SNILVEBRANT JASTRAND MBUIJS JSANDSTROM MHONARVAR HORLOVA ATOLMACHEV VHOBER S, "ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers", Cancer Res., (20151000), vol. 75, no. 20, pages 4364 - 71 | - GAROUSI JLINDBO SHONARVAR HVELLETTA JMITRAN BALTAI MORLOVA ATOLMACHEV VHOBER S, "Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6", Bioconjug Chem., (20161116), vol. 27, no. 11, pages 2678 - 2688 | - GAROUSI JLINDBO SBORIN JVON WITTING EVOROBYEVA AOROUJENI MMITRAN BORLOVA ABUIJS JTOLMACHEV V, "Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER -expressing tumours", Eur J Pharm Biopharm., (20190100), vol. 134, doi:10.1016/j.ejpb.2018.11.004, pages 37 - 48, XP085555750 DOI: http://dx.doi.org/10.1016/j.ejpb.2018.11.004 | - JONSSON ADOGAN JHERNE NABRAHMSEN LNYGREN PA, "Engineering of a femtomolar affinity binding protein to human serum albumin", Protein Eng Des Sel, (20080800), vol. 21, no. 8, doi:10.1093/protein/gzn028, pages 15 - 27, XP055047773 DOI: http://dx.doi.org/10.1093/protein/gzn028 | - KRASNIQI AD'HUYVETTER MDEVOOGDT NFREJD FYSORENSEN JORLOVA AKEYAERTS MTOLMACHEV V, "Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology", J Nucl Med., (20180600), vol. 59, no. 6, pages 885 - 891 | - LINDBO SGAROUSI JASTRAND M et al., "Influence of histidine-containing tags on the biodistribution of ADAPT scaffold proteins", Bioconjug Chem., (20160000), vol. 2, pages 16 - 726 | - LINDBO SGAROUSI JMITRAN BALTAI MBUIJS JORLOVA AHOBER STOLMACHEV V, "Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label", J Nucl Med., (20180100), vol. 59, no. 1, pages 93 - 99 | - NILVEBRANT JHOBER S, "The albumin-binding domain as a scaffold for protein engineering", Comput Struct Biotechnol J, vol. 2013, no. 6, pages 1 - 8 | - NILVEBRANT JHOBER S, "Engineering of Bispecific Affinity Proteins with High Affinity for ERBB and Adaptable Binding to Albumin", PLOS ONE, (20140800), vol. 9, no. 8 | - PRICE EWORVIG C, "Matching chelators to radiometals for radiopharmaceuticals", Chem Soc Rev., (20140107), vol. 43, no. 1, doi:10.1039/C3CS60304K, pages 260 - 90, XP055397567 DOI: http://dx.doi.org/10.1039/C3CS60304K | - TOLMACHEV VMUME ESJOBERG SFREJD FYORLOVA A, "Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER -binding Affibody molecules", Eur J Nucl Med Mol Imaging, (20090000), vol. 36, pages 692 - 701, XP019706049 | - TOLMACHEV VORLOVA AANDERSSON K, "Methods for radiolabelling of monoclonal antibodies", Methods Mol Biol., (20140000), vol. 1060, pages 309 - 30 | - WESTERLUND KALTAI MMITRAN BKONIJNENBERG MOROUJENI MATTERBY CDE JONG MORLOVA AMATTSSON JMICKE P, "Radionuclide Therapy of HER -Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting: In Vivo Proof of Principle", J Nucl Med., (20180000), vol. 59, pages 1092 - 1098 | - WALLBERG HORLOVA A, "Slow internalization of anti-HER2 synthetic affibody monomer In-DOTA-ZHER2: -pep2: implications for development of labeled tracers", Cancer Biother Radiopharm., (20080000), vol. 23, pages 435 - 442 |